Product name : JNJ 7706621
Item : cc-474
Price : 200mg, $850;500mg, $1650; 1g $2250; 2g, $3450
contact : Send inquiry to: info@acesobio.com,or by fax to: 1-845-673-1239.
CAS : 443797-96-4
Molecular Weight : 394.36
Formula : C₁₅H₁₂F₂N₆O₃S
Storage : at -20°C
Additional information : We offer significant discount for larger quantity order
|
Details: | |||||||||||||||||||||||||
JNJ-7706621 is a dual cyclin-dependent kinases and aurora kinases inhibitor with IC50 of 9 and 11 nM for CDK1/Cyclin B and aurora-A, respectively. JNJ-7706621 blocked proliferation of cancer cells regardless of their p53, retinoblastoma or P-glycoprotein status and induced cell death by activating apoptosis. JNJ-7706621 was about 10 fold less effective at inhibiting proliferation of normal cells. Flow cytometric analysis of DNA content in human tumor cells showed that JNJ-7706621 delayed progression through G1 and arrested the cell cycle at the G2/M phase. JNJ-7706621 also decreased CDK1 kinase activity, altered CDK1 phosphorylation status and blocked signaling to downstream substrates of CDKs. Additional cellular effects including endoreduplication and reduced histone H3 phosphorylation were also observed due to inhibition of Aurora kinase. JNJ-7706621 demonstrated significant inhibition of tumor growth in a variety of tumor types in nude mice xenograft models. In vitro cell proliferation assays IC50 (μM): HeLa (IC50=0.286), HCT-116 (IC50=0.189), PC3 (IC50=0.112). JNJ-7706621 is not affected by P-glycoprotein. [1]
Reference:
[1] Cancer Res. 2005, 65, 9038-9046.
Chemical Information
PLEASE KEEP THE PRODUCT UNDER -20℃ FOR LONG-TERM STORAGE.
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
|
Related Products : |
|
|
|
|
||||||||
|
|
|
|